TY - JOUR
T1 - Assessment of individual and standardized glucagon kinetics in healthy humans
AU - Laurenti, Marcello C.
AU - Vella, Adrian
AU - Adams, Jon D.
AU - Schembri Wismayer, Daniel J.
AU - Egan, Aoife M.
AU - Man, Chiara Dalla
N1 - Funding Information:
This study was supported by US National Institutes of Health DK78646, DK116231, and DK126206 (to A. Vella), the Mayo Clinic General Clinical Research Center, University of Padova Research Grant CPDA145405, and Mayo Clinic General Clinical Research Center (UL1 TR000135).
Publisher Copyright:
Copyright © 2021 the American Physiological Society
PY - 2021/1
Y1 - 2021/1
N2 - Impaired glucose tolerance arises out of impaired postprandial insulin secretion and delayed suppression of glucagon. These defects occur early and independently in the pathogenesis of prediabetes. Quantification of the contribution of a-cell dysfunction to glucose tolerance has been lacking because knowledge of glucagon kinetics in humans is limited. Therefore, in a series of experiments examining the interaction of glucagon suppression with insulin secretion we studied 51 nondiabetic subjects (age = 54 ± 13 yr, BMI = 28 ± 4 kg/m2). Glucose was infused to mimic the systemic appearance of an oral challenge. Somatostatin was used to inhibit endogenous hormone secretion. 120 min after the start of the experiment, glucagon was infused at 0.65 ng/ kg/min. The rise in glucagon concentrations was used to estimate its kinetic parameters [volume of distribution (Vd), half-life (t1/2), and clearance rate (CL)]. A single-exponential model provided the best fit for the data, and individualized kinetic parameters were estimated: Vd = 8.2 ± 2.7 L, t1/2=4 ± 1.1 min, CL = 1.4 ± 0.33 L/min. Stepwise linear regression was used to correlate Vd with BMI and sex (R2adj = 0.44), whereas CL similarly correlated with lean body mass or BSA (both R2 = 0.28). This enabled the development of a population-based model using anthropometric characteristics to predict Vd and CL. These data demonstrate that it is feasible to derive glucagon kinetic parameters from anthropometric characteristics, thereby enabling quantitation of the rate of glucagon appearance in the systemic circulation in large populations.
AB - Impaired glucose tolerance arises out of impaired postprandial insulin secretion and delayed suppression of glucagon. These defects occur early and independently in the pathogenesis of prediabetes. Quantification of the contribution of a-cell dysfunction to glucose tolerance has been lacking because knowledge of glucagon kinetics in humans is limited. Therefore, in a series of experiments examining the interaction of glucagon suppression with insulin secretion we studied 51 nondiabetic subjects (age = 54 ± 13 yr, BMI = 28 ± 4 kg/m2). Glucose was infused to mimic the systemic appearance of an oral challenge. Somatostatin was used to inhibit endogenous hormone secretion. 120 min after the start of the experiment, glucagon was infused at 0.65 ng/ kg/min. The rise in glucagon concentrations was used to estimate its kinetic parameters [volume of distribution (Vd), half-life (t1/2), and clearance rate (CL)]. A single-exponential model provided the best fit for the data, and individualized kinetic parameters were estimated: Vd = 8.2 ± 2.7 L, t1/2=4 ± 1.1 min, CL = 1.4 ± 0.33 L/min. Stepwise linear regression was used to correlate Vd with BMI and sex (R2adj = 0.44), whereas CL similarly correlated with lean body mass or BSA (both R2 = 0.28). This enabled the development of a population-based model using anthropometric characteristics to predict Vd and CL. These data demonstrate that it is feasible to derive glucagon kinetic parameters from anthropometric characteristics, thereby enabling quantitation of the rate of glucagon appearance in the systemic circulation in large populations.
KW - A-cell
KW - Clearance
KW - Glucagon
KW - Impaired glucose tolerance
KW - Prediabetes
UR - http://www.scopus.com/inward/record.url?scp=85099721329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099721329&partnerID=8YFLogxK
U2 - 10.1152/AJPENDO.00488.2020
DO - 10.1152/AJPENDO.00488.2020
M3 - Article
C2 - 33135460
AN - SCOPUS:85099721329
SN - 0193-1849
VL - 320
SP - E71-E77
JO - American Journal of Physiology - Endocrinology and Metabolism
JF - American Journal of Physiology - Endocrinology and Metabolism
IS - 1
ER -